Promising New Treatment Combination Shows Critically important Benefit in Generalized Myasthenia Gravis
Generalized Myasthenia Gravis (gMG) is a chronic autoimmune neuromuscular disease that causes weakness in voluntary muscles. Recent clinical trial results offer a hopeful outlook for individuals living with this challenging condition. A new combination therapy, utilizing cemdisiran alongside pozelimab, is demonstrating significant improvements in symptom control and quality of life, according to data presented from the Phase 3 NIMBLE trial.
Understanding the Assessments
Before diving into the results, it’s helpful to understand how improvement is measured in gMG. Physicians utilize the Quantitative Myasthenia Gravis (QMG) score, a comprehensive assessment evaluating:
Vision
Speaking and swallowing
Breathing
Limb function
Additionally, the Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score assesses how gMG impacts your ability to perform everyday tasks.
Cemdisiran Demonstrates Superior Efficacy
The NIMBLE trial revealed cemdisiran, when combined with pozelimab, led to greater improvements compared to placebo and cemdi-poze alone. Here’s a breakdown of the key findings:
MG-ADL Score Improvement: Cemdisiran showed a placebo-adjusted treatment difference of -2.30 compared to -1.74 with cemdi-poze. The mean change from baseline was -4.52 with cemdisiran versus -3.96 with cemdi-poze.
QMG Score Improvement: The placebo-adjusted treatment difference in QMG total score favored cemdisiran (-2.77) over cemdi-poze (-1.86). Mean change from baseline also showed a benefit with cemdisiran (-4.24) compared to cemdi-poze (-3.32).
These results suggest cemdisiran enhances the effectiveness of pozelimab,potentially offering more significant relief from gMG symptoms.
A Favorable Safety Profile
Importantly, the combination therapy proved safe in the NIMBLE trial. While pozelimab carries a warning about the potential for serious meningococcal infections, no such infections were reported during the study.
Here’s a closer look at the safety data:
No Treatment Discontinuations: No patients stopped treatment due to adverse events (AEs) within the first 24 weeks.
Treatment-emergent AEs: approximately 69% of patients receiving cemdisiran experienced TEAEs, compared to 81% with cemdi-poze and 77% with placebo. Serious TEAEs: Serious TEAEs were reported by only 3% of patients on cemdisiran, versus 9% on cemdi-poze.
Common AEs: The most frequently reported AEs across all groups included worsening of MG, upper respiratory tract infections, urinary tract infections, nasopharyngitis, and headache.
* no Deaths: No deaths were reported during the 24-week placebo-controlled portion of the trial.
Building on Previous successes
The positive results from NIMBLE build upon earlier findings. the cemdisiran and pozelimab combination has already shown promise in treating paroxysmal nocturnal hemoglobinuria (PNH). In a Phase 3 trial (ACCESS-1), this combination helped patients with PNH achieve and maintain better disease control than standard treatment.
Furthermore, cemdisiran is currently being investigated for its potential in treating geographic atrophy, a leading cause of vision loss due to age-related macular degeneration. This broad range of clinical investigations highlights the versatility and potential of cemdisiran.
What This Means for You
If you are living with gMG, these findings offer a reason for optimism. The cemdisiran and pozelimab combination represents a potentially significant advancement in treatment options. While the NIMBLE results are still investigational, they strongly suggest this therapy could provide more effective symptom relief and improve your overall quality of life.
Talk to your neurologist about whether this combination therapy might be a suitable option for you,and stay informed about the latest developments in gMG treatment.
References:
- Regeneron. Regeneron announces positive results from phase 3 trial in generalized myasthenia gravis. News Release. August 26